{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T09:08:07Z","timestamp":1779700087783,"version":"3.53.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bioorg.2026.109962","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T15:28:03Z","timestamp":1778340483000},"page":"109962","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Exploiting PKM2-PARP1 dependency: Isoselenazolium-olaparib conjugates achieve multimodal PKM2 suppression"],"prefix":"10.1016","volume":"178","author":[{"given":"Pavels","family":"Dimitrijevs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Makrecka-Kuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Zelencova-Gopejenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanna","family":"Rudevica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ksenija","family":"Korotkaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Zajakina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristofers","family":"Rudzitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Bogucka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Hyv\u00f6nen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodors","family":"Pantelejevs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Arsenyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.109962_bb0005","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.00159","article-title":"Pyruvate kinase M2 and cancer: the role of PKM2 in promoting tumorigenesis","volume":"10","author":"Zahra","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2026.109962_bb0010","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.18632\/oncotarget.13703","article-title":"Pyruvate kinase M2 (PKM2) expression correlates with prognosis in solid cancers: a meta-analysis","volume":"8","author":"Zhu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2026.109962_bb0015","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1126\/science.1211485","article-title":"Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses","volume":"334","author":"Anastasiou","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2026.109962_bb0020","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12929-025-01170-6","article-title":"Nuclear PKM2: a signal receiver, a gene programmer, and a metabolic modulator","volume":"32","author":"Chen","year":"2025","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.bioorg.2026.109962_bb0025","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s13238-019-0618-z","article-title":"PKM2 coordinates glycolysis with mitochondrial fusion and oxidative phosphorylation","volume":"10","author":"Li","year":"2019","journal-title":"Protein Cell"},{"key":"10.1016\/j.bioorg.2026.109962_bb0030","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/s41589-022-00997-6","article-title":"Targeting allosteric regulation of cancer metabolism","volume":"18","author":"Kremer","year":"2022","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bioorg.2026.109962_bb0035","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.cell.2012.07.018","article-title":"PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis","volume":"150","author":"Yang","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2026.109962_bb0040","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12943-015-0490-2","article-title":"PKM2 promotes tumor angiogenesis by regulating HIF-1\u03b1 through NF-\u03baB activation","volume":"15","author":"Azoitei","year":"2016","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bioorg.2026.109962_bb0045","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature10598","article-title":"Nuclear PKM2 regulates \u03b2-catenin transactivation upon EGFR activation","volume":"480","author":"Yang","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.109962_bb0050","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.canlet.2020.11.018","article-title":"Pyruvate kinase M2 (PKM2) in cancer and cancer therapeutics","volume":"503","author":"Zhu","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bioorg.2026.109962_bb0060","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s11011-021-00690-y","article-title":"A short review on cross-link between pyruvate kinase (PKM2) and glioblastoma multiforme","volume":"36","author":"Verma","year":"2021","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.bioorg.2026.109962_bb0065","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.canlet.2018.02.028","article-title":"Nuclear EGFR-PKM2 axis induces cancer stem cell-like characteristics in irradiation-resistant cells","volume":"422","author":"Shi","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bioorg.2026.109962_bb0070","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.celrep.2016.03.070","article-title":"PARP inhibition suppresses growth of EGFR-mutant cancers by targeting nuclear PKM2","volume":"15","author":"Li","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.bioorg.2026.109962_bb0075","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/jbt.21673","article-title":"In vitro effects of some flavones on human pyruvate kinase isoenzyme M2","volume":"29","author":"Aslan","year":"2015","journal-title":"J. Biochem. Mol. Tox."},{"key":"10.1016\/j.bioorg.2026.109962_bb0080","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1080\/14756366.2017.1404591","article-title":"Synthesis and antitumor activity of novel 2, 3-didithiocarbamate substituted naphthoquinones as inhibitors of pyruvate kinase M2 isoform","volume":"33","author":"Ning","year":"2018","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109962_bb0085","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1021\/acs.jmedchem.3c01512","article-title":"Mechanistic investigation of thiazole-based pyruvate kinase M2 inhibitor causing tumor regression in triple-negative breast cancer","volume":"67","author":"Das","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109962_bb0090","doi-asserted-by":"crossref","first-page":"21595","DOI":"10.1038\/s41598-020-78620-8","article-title":"Fused isoselenazolium salts suppress breast cancer cell growth by dramatic increase in pyruvate-dependent mitochondrial ROS production","volume":"10","author":"Makrecka-Kuka","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2026.109962_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115504","article-title":"Development of isoselenazolium chlorides as selective pyruvate kinase isoform M2 inhibitors","volume":"257","author":"Dimitrijevs","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109962_bb0100","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1021\/acs.jmedchem.9b00726","article-title":"Dual inhibitors of human DNA topoisomerase II and other cancer-related targets","volume":"63","author":"Skok","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109962_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.188866","article-title":"Therapeutic strategies of dual-target small molecules to overcome drug resistance in cancer therapy","volume":"1878","author":"Ye","year":"2023","journal-title":"Biochimica et Biophysica acta (BBA) - reviews on Cancer"},{"key":"10.1016\/j.bioorg.2026.109962_bb0110","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41589-020-0469-1","article-title":"Unifying principles of bifunctional, proximity-inducing small molecules","volume":"16","author":"Gerry","year":"2020","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bioorg.2026.109962_bb0115","doi-asserted-by":"crossref","first-page":"5842","DOI":"10.1002\/ejoc.201500582","article-title":"Fused selenazolinium salt derivatives with a se\u2013N+ bond: preparation and properties","volume":"2015","author":"Arsenyan","year":"2015","journal-title":"Eur. J. Org. Chem."},{"key":"10.1016\/j.bioorg.2026.109962_bb0120","doi-asserted-by":"crossref","first-page":"40921","DOI":"10.1039\/C8RA09152H","article-title":"NMR-based investigations of acyl-functionalized piperazines concerning their conformational behavior in solution","volume":"8","author":"Wodtke","year":"2018","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2026.109962_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106529","article-title":"Selective PARP1 inhibitors, PARP1-based dual-target inhibitors, PROTAC PARP1 degraders, and prodrugs of PARP1 inhibitors for cancer therapy","volume":"186","author":"Peng","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2026.109962_bb0130","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1016\/j.bmc.2017.05.058","article-title":"Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy","volume":"25","author":"Yuan","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109962_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114574","article-title":"Design, synthesis and pharmacological evaluation of new PARP1 inhibitors by merging pharmacophores of olaparib and the natural product alantolactone","volume":"240","author":"Kayumov","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109962_bb0140","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.3390\/pharmaceutics14122571","article-title":"Olaparib conjugates with selenopheno[3,2-c]quinolinone inhibit PARP1 and reverse ABCB1-related multidrug resistance","volume":"14","author":"Makrecka-Kuka","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bioorg.2026.109962_bb0145","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S1096-4959(03)00081-2","article-title":"Pyruvate kinase: current status of regulatory and functional properties","volume":"135","author":"Enriqueta Mu\u00f1oz","year":"2003","journal-title":"Comp. Biochem. Physiol. B: Biochem. Mol. Biol."},{"key":"10.1016\/j.bioorg.2026.109962_bb0150","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/j.1460-2075.1986.tb04236.x","article-title":"The structure of cat muscle pyruvate kinase","volume":"5","author":"Muirhead","year":"1986","journal-title":"EMBO J."},{"key":"10.1016\/j.bioorg.2026.109962_bb0155","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1002\/pro.505","article-title":"Human pyruvate kinase M2: a multifunctional protein","volume":"19","author":"Gupta","year":"2010","journal-title":"Protein Sci."},{"key":"10.1016\/j.bioorg.2026.109962_bb0160","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.45068","article-title":"Functional cross-talk between allosteric effects of activating and inhibiting ligands underlies PKM2 regulation","volume":"8","author":"Macpherson","year":"2019","journal-title":"eLife"},{"key":"10.1016\/j.bioorg.2026.109962_bb0165","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/carcin\/bgz180","article-title":"EGFR-PKM2 signaling promotes the metastatic potential of nasopharyngeal carcinoma through induction of FOSL1 and ANTXR2","volume":"41","author":"Chen","year":"2020","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bioorg.2026.109962_bb0170","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1073\/pnas.1311249111","article-title":"JMJD5 regulates PKM2 nuclear translocation and reprograms HIF-1\u03b1\u2013mediated glucose metabolism","volume":"111","author":"Wang","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bioorg.2026.109962_bb0175","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.7150\/ijbs.59855","article-title":"Specific pyruvate kinase M2 inhibitor, compound 3K, induces autophagic cell death through disruption of the glycolysis pathway in ovarian cancer cells","volume":"17","author":"Park","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.bioorg.2026.109962_bb0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/8396023","article-title":"PKM2 promotes breast cancer progression by regulating epithelial mesenchymal transition","volume":"2020","author":"Xiao","year":"2020","journal-title":"Anal. Cell. Pathol."},{"key":"10.1016\/j.bioorg.2026.109962_bb0185","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.cmet.2023.12.003","article-title":"Metabolic switch regulates lineage plasticity and induces synthetic lethality in triple-negative breast cancer","volume":"36","author":"Zhang","year":"2024","journal-title":"Cell Metab."},{"key":"10.1016\/j.bioorg.2026.109962_bb0190","unstructured":"C. Ma, X. Zu, K. Liu, A.M. Bode, Z. Dong, Z. Liu, D.J. Kim, Knockdown of Pyruvate Kinase M Inhibits Cell Growth and Migration by Reducing NF-kB Activity in Triple-Negative Breast Cancer Cells, (n.d.)."},{"key":"10.1016\/j.bioorg.2026.109962_bb0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0203745","article-title":"PKM2 and HIF-1\u03b1 regulation in prostate cancer cell lines","volume":"13","author":"Hasan","year":"2018","journal-title":"PloS One"},{"key":"10.1016\/j.bioorg.2026.109962_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115434","article-title":"Synthesis of novel dual target inhibitors of PARP and HSP90 and their antitumor activities","volume":"28","author":"Lin","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109962_bb0205","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3390\/biom11070981","article-title":"Dual PARP and RAD51 inhibitory drug conjugates show synergistic and selective effects on breast cancer cells","volume":"11","author":"Malka","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.bioorg.2026.109962_bb0210","doi-asserted-by":"crossref","first-page":"19586","DOI":"10.1021\/acs.jmedchem.4c01910","article-title":"A Prostate-Specific Membrane Antigen-targeting small molecule\u2013drug conjugate strategy to overcome the hematological toxicity of Olaparib","volume":"67","author":"Chen","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109962_bb0215","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3390\/biom16010165","article-title":"Development of mitochondria-targeted PARP inhibitors","volume":"16","author":"Dimitrijevs","year":"2026","journal-title":"Biomolecules"},{"key":"10.1016\/j.bioorg.2026.109962_bb0220","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/ncb2629","article-title":"ERK1\/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect","volume":"14","author":"Yang","year":"2012","journal-title":"Nat. Cell Biol."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826004980?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826004980?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T08:52:03Z","timestamp":1779699123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826004980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":43,"alternative-id":["S0045206826004980"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109962","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploiting PKM2-PARP1 dependency: Isoselenazolium-olaparib conjugates achieve multimodal PKM2 suppression","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109962","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109962"}}